Navigation Links
Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
Date:8/13/2008

SAN MATEO, Calif., Aug. 13 /PRNewswire/ -- Anthera Pharmaceuticals Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, today announced the completion of a $19 Million equity financing. New investors Caxton Advantage Life Sciences Fund (New York, NY) and HBM BioCapital (Cayman Islands) led the financing, and Rachel Leheny, Ph.D. Managing Director of Caxton Advantage Venture Partners (the General Partner of Caxton Advantage Life Sciences Fund) will join Anthera's Board of Directors. The financing also included existing investors VantagePoint Venture Partners, Sofinnova Ventures, Pappas Ventures and Mitsubishi International Corporation.

In addition, the company announced the appointment of Christopher S. Henney as Chairman of the Board. Dr. Henney has served as an independent director of Anthera since 2006. Dr. Henney is a co-founder of three major publicly held U.S. biotechnology companies: Immunex‚ ICOS and Dendreon‚ and has been associated with the formation of several others. Most recently Dr. Henney has served as Chairman and Chief Executive Officer of Dendreon (Nasdaq: DNDN) and as Chairman of SGX Pharmaceuticals (Nasdaq: SGXP) and of Oncothyreon (Nasdaq: ONTY).

"We are delighted to have Caxton Advantage and HBM, two premier health care funds, lead
'/>"/>

SOURCE Anthera Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. Anthera Pharmaceuticals Forms Scientific Advisory Board
3. Anthera Presents Data on Varespladib at ATVB Meeting
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 16, 2015 OncoTAb, Inc., ... (UNC Charlotte) spin-out company, announced today the appointment ... M.D., as Chief Operating Officer (COO). Cooper brings ... in developing clinical diagnostic and biotechnology platforms in ... , Cooper’s extensive career transcends the field of ...
(Date:4/16/2015)... , April 16, 2015 /PRNewswire/ - Portage Biotech ... Canadian Securities Exchange: PBT.U), is pleased to announce that ... Show on April 25, 2015 to be held in ... Gregory Bailey and Mr. James Mellon ... and an update on the key programs at its ...
(Date:4/16/2015)... ChemRar High Tech ... R&D group, and Lancet, Russian Distribution Company, ... commercialization of new medicines in ... stimulate the innovative development of the Russian ... ,     (Logo: http://photos.prnewswire.com/prnh/20150416/739742-b) , Through ...
(Date:4/16/2015)... Calif. , April 16, 2015  Scientists from ... "New Drugs on the Horizon," at the American Association ... Philadelphia, PA on Sunday, April 19, 2015 ... Ph.D., Cleave,s Director of Biology, will present new in ... a first-in-class, oral inhibitor of p97, a critical enzyme ...
Breaking Biology Technology:OncoTAb Names Dr. David L. Cooper as COO 2Portage to Present at Master Investor 2015 in London, UK 2Portage to Present at Master Investor 2015 in London, UK 3Portage to Present at Master Investor 2015 in London, UK 4Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3
... COLUMBIA, Md., Sept. 13 Martek Biosciences,Corporation (Nasdaq: ... presenting at the,upcoming UBS Global Life Sciences Conference ... September 24-27, 2007 at the Grand Hyatt in ... on Tuesday, September 25th at,3:00 p.m. Eastern Time. ...
... 13 Vet-Stem, Inc., the global leader,in regenerative ... to the Central Veterinary Research Laboratory (CVRL) of,Dubai ... the laboratory to,offer adipose- derived stem cell services ... ruler of Dubai and Prime Minister of the ...
... Together Thought Leaders,in Life Sciences and Clinical Diagnostics ... Netherlands, Sept. 13 Luminex,Corporation (Nasdaq: LMNX ... the agenda for Planet xMAP Europe 2007, the ... will be,held 2-3 October at the Berlage,s Exchange ...
Cached Biology Technology:Vet-Stem and Central Veterinary Research Labs of Dubai Sign Exclusive License 2Luminex Corporation Hosts the Fifth Annual Planet xMAP Europe 2007 Symposium 2Luminex Corporation Hosts the Fifth Annual Planet xMAP Europe 2007 Symposium 3
(Date:4/2/2015)... Md. , April 2, 2015 At ... Salt Lake City , the American College ... of five new directors to its Board.  Members of ... the ACMG and for forming and advancing its policies ... medical genetics profession. "It,s an eventful time ...
(Date:4/2/2015)... 2015 Fingerprint Cards (FPC) has ... from the distributor World Peace Industrial Group (WPI), part ... although the major part of the shipments will take ... by smartphone manufacturers in China . ... the communicated revenue guidance of + 1 000 MSEK for ...
(Date:4/1/2015)... Medisafe ™, the leading global medication management platform with ... Android smartphones and tablets, announces today that ... allow patients to track and correlate their adherence directly ... be able to visualize in real-time how taking medication ... glucose levels and blood pressure. "Patients need ...
Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... living on the Port Valdez seafloor to stabilize after ... at the University of Alaska Fairbanks. "The earthquake, ... tsunami waves that followed, impacted every marine community in ... professor at the UAF School of Fisheries and Ocean ...
... YORK (April 24, 2011) -- A team of scientists ... Weill Cornell Medical College has shed light on the ... the cell membranes of neurons that modulate the transfer ... The research, published today in the journal Nature, ...
... ,Chicago, IL Stephen Maturo, MD, of Boston, MA, ... Award for outstanding achievement in the field of pediatric ... (EMG) in Children with Vocal Fold Mobility: Results of ... 29 May 1, 2011, in Chicago, IL. The ...
Cached Biology News:Port Valdez invertebrates stabilized 26 years after quake 2Molecular movements of neural transporters unveiled 2Molecular movements of neural transporters unveiled 3Molecular movements of neural transporters unveiled 4Molecular movements of neural transporters unveiled 5Stephen Maturo, M.D., ear, nose and throat specialist, receives Charles Ferguson Award 2
Mouse monoclonal [SPM217] to Secretory Component Glycoprotein ( Abpromise for all tested applications)....
Rabbit polyclonal to FLIP ( Abpromise for all tested applications). entrezGeneID: 8837 SwissProtID: O15519...
... [EP282Y] to Asparagine synthetase ( ... applications). Antigen: ... residues in the C-terminus of ... Entrez GeneID: 440 ...
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 25 tests...
Biology Products: